cyrilzakka/clinical-trials huggingface dataset:
The Impact of Pain Assessment on the Hospital Length of Stay of Patients in a Rehabilitation Unit

The financing of the Belgian hospitals is based on a system taking into account the length of hospitalization of a given patient according to his/her pathology, his/her age and his/her geriatric characteristics. This system encourages all hospital to lower the hospitalization duration to the national average for these criteria. This results in better efficiency in the management of hospitalizations but also means a swifter transfer to structures exempted from this system such as revalidation units, nursing homes and psychiatric units. An assessment of the differences in the medical practice, in terms of quality and outcomes of care, is essential for any reform willing to reduce medical costs.

Pain management is part of the quality indicators within hospitals. Pain is defined by the International Association for the Study of Pain as "an unpleasant sensory and emotional experience, associated to present or potential tissue damage, or described in terms of such a damage". Several studies have showed that pain affects the quality of life and impacts the daily activities. Acute or chronic pain can cause adverse symptoms such as sleep disturbance, appetite loss, decreased concentration, mood changes and the disruption of familial, work and social activities. Pain might also slow down revalidation processes. A study performed by Aprile et al showed that pain negatively influenced the rehabilitation program of a quarter of the patients having had a stroke. The functional recovery was slower and the costs were higher.

The aim of this study is to determine if the systematic evaluation of the pain of a patient hospitalized in a revalidation unit has an impact on his/her length of stay.


Eligibility Criteria:
Inclusion Criteria:

* Sequential inclusion of all patients hospitalized in the chronic revalidation hospital unit of the CHU Brugmann - Queen Astrid site

Exclusion Criteria:

* Pathological cognitive state (MMS\<23/30)
An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 Study

This is an extension study, to provide continued access to PRO 140 to subjects who complete participation in PRO140_CD02 and continue to receive clinical benefit and would require PRO 140 to form a viable regimen, in the opinion of the treating physician. The patient population for this trial are treatment-experienced HIV infected patients with CCR5-tropic virus who demonstrate evidence of HIV-1 suppression after successfully completed 24 weeks of treatment in the PRO140_CD02 study.


Eligibility Criteria:
Inclusion Criteria: Potential subjects are required to meet all of the following criteria for enrollment into the study.

1. Subjects who have completed 24 weeks of treatment in PRO 140_CD 02 study, and Investigator believes subject requires continued access to PRO 140 in order to continue deriving clinical benefit and maintain HIV-1 viral suppression
2. HIV-1 RNA ≤ 50 copies/ml at T23 Visit in PRO140_CD02 study
3. Both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (e.g., barrier contraceptives \[male condom, female condom, or diaphragm with a spermicidal gel\], hormonal contraceptives \[implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings\], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized).

   Females of childbearing potential must have a negative urine pregnancy test prior to receiving the first dose of study drug.
4. Willing and able to participate in all aspects of the study, including use of SC medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.

Exclusion Criteria: Potential subjects meeting any of the following criteria will be excluded from enrollment.

1. Not currently enrolled in PRO 140_CD 02 study
2. Any active infection or malignancy requiring acute therapy (with the exception of local cutaneous Kaposi's sarcoma)
3. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study
4. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety measures
A Pilot Study of Lithium in Progressive Multiple Sclerosis

The purpose of this study is to determine whether lithium carbonate is safe, well-tolerated, and effective at treating progressive forms of multiple sclerosis.

In progressive multiple sclerosis (MS), patients experience worsening disability through a combination of inflammatory and neuro-degenerative processes. To test whether low-dose lithium carbonate ameliorates disability accumulation in progressive MS, patients with progressive MS were randomly assigned to take lithium in either the first or second year of a two-year trial. The trial was designed as a cross-over study to maximize exposure to lithium to for two reasons: 1) To increase the number of persons with MS exposed to lithium for purposes of assessing safety and tolerance; and 2) To increase the power to detect changes in the primary radiological outcome (change in brain volume) and also in secondary clinical outcomes (disability, mood, fatigue, cognition).

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of a progressive subtype of multiple sclerosis by revised 2005 McDonald Criteria.
* EDSS of 3.0-6.5
* Ages 30-65
* Must be mentally capable of providing informed consent and following study guidelines.

Exclusion Criteria:

* Relapse or steroid treatment within 1 month of trial entry.
* Any current or previous treatment with mitoxantrone, azathioprine, methotrexate, mycophenolate, cyclophosphamide, or any experimental therapy.
* Women who are pregnant, wishing to become pregnant in the coming 30 months, or are breastfeeding.
* Sexually active women unwilling to use reliable contraception (oral contraceptives, condom, IUD).
* Patients with known kidney dysfunction or creatinine \>1.4; known cardiac arrhythmia or significant conduction abnormality on EKG; uncontrolled thyroid disease or TSH \>20% above the upper limit of normal; uncontrolled psoriasis, HIV, or any other severe medical condition.
* Patients with a history of unstable psychiatric illness or active severe depression.
* Patients with a history of seizure.
* Concurrent use of any of the following medications: Antipsychotics, diuretics, digoxin, or iodide salts.
* Use of non-steroidal anti-inflammatory drugs (NSAIDs) 5 or more days a week.
* Patients with a history of substance abuse in the past year.
* Patients sensitive to gadolinium, or who are unable to undergo the required number of MRI scans.
* Unable to speak or understand sufficient English to consent or complete study procedures.
* Patients unable or unwilling to provide informed consent.
The Efficacy and Treatment Adherence With an Integrated Program on HbA1c Scores in Patients With Type 2 Diabetes

It is hypothesized for this study that the coupling of the Millon Behavioral Medicine Diagnostic, biopsychosocial evaluation, motivational interviewing, relapse prevention, and ongoing support can produce improved outcomes with diabetics who have previously been unsuccessful with the traditional care. This study examined the relationship between patients' HbA1c levels and patients' involvement in the ASMART program, a multifaceted program involving psychological intervention. The study was conducted through the Kosciusko Health Department and funded by K21 Health Foundation.

The study involved 182 Type 2 Diabetes patients with an HbA1c score above 7, reflecting poor control of diabetes. The experimental group consisted of 124 patients who joined the ASMART program, while the control group consisted of 60 patients who continued to receive traditional care. Statistical analysis involved comparing pretest \& posttest HbA1c levels for the experimental group and the control group.

Eligibility Criteria:
Inclusion Criteria:

* Type 2 Diabetes patients with an HbA1c score over 7

Exclusion Criteria:

* No Type 1 patients
* No children under the age of 18
A Pilot Study of Non-invasive Brain Stimulation to Boost the Efficacy of Psychotherapy in a Community Sample of People Who Drink Alcohol

The goal of this small (n=75) proof-of-concept randomized clinical trial is to test the effects of transcranial alternating current stimulation (tACS) during motivational interviewing (MI) sessions with participants who drink at above the low-risk level. Participants will be randomized to receive either MI with active stimulation, MI with sham stimulation, or a delayed treatment group that receives MI with no stimulation. Measures will include brain imaging, alcohol use, cannabis use, risk-taking behavior, emotions, and others. Participants who are randomized to the delayed-treatment group will not receive brain imaging.

This proof-of-concept randomized clinical trial will recruit n=75 people with problematic levels of drinking who are considering treatment for their alcohol use. These participants will be randomized to one of three conditions: a condition that applies active tACS during an MI session (MI+tACS), a condition that applies sham stimulation during an MI session (MI+sham), or a waitlist control condition (MI-only). Only participants the MI+tACS and MI+sham conditions will be included in the brain imaging portion of the study. One month after their intervention session, all participants will report their use of alcohol in the prior 30 days via an online assessment battery. This will allow us to test the effects of tACS on within-session client speech and outcomes.

Participants will have magnetoencephalography (MEG) scans including rest and an alcohol cue task to measure the acute effects of brain stimulation. Participants will also have MRI scans including structure and rest. The Motivational Interviewing Skill Code (MISC 2.5) and the CASAA Application for Coding Treatment Interactions (CACTI) will be used to assess counselor and participant speech in the recorded MI sessions and to ensure that sessions comply with the principles of MI.

Eligibility Criteria:
Inclusion criteria:

* Self-identify as having problem drinking
* Right-handed
* Age 21-60 years
* AUDIT score indicating risky drinking

Exclusion criteria:

* Left-handed or ambidextrous
* Currently engaged in treatment for alcohol use disorder
* Receiving treatment for alcohol use disorder within the prior 12 months
* History of brain injury or neurological diagnosis
* Evidence of current psychosis
* Past-year substance use disorder other than alcohol, marijuana, or nicotine
* Current or history of severe alcohol withdrawal
* MRI/tACS contraindications including pregnancy
* Impaired hearing (psychotherapy using American Sign Language is not possible within the scope of the proposed study)
* Insufficient corrected visual acuity to complete the assessment instruments
* Unable to read/speak English fluently
* Unable to provide valid informed consent
Incidence of Diabetes and Metabolic Disorders After TIPS in Cirrhotic Patients

Decompensated cirrhosis is associated with sarcopenia. TIPS is an efficient treatment of portal hypertension. Based on our retrospective data, TIPS induces in 30% of cirrhotic patients metabolic disorders associated with diabetes or pre-diabetes. The main objective is to measure the cumulative incidence of diabetes and pre-diabetes 6 months after TIPS insertion.

Based on our retrospective data, we expect that one-third of cirrhotic patients develop glucose dysregulation after TIPS. A better knowledge of the metabolic disorders related to the TIPS could allow to prevent the deleterious effects of the TIPS on the disease (decrease of the insulin-sensitivity, fat gain ...), by simple interventions on diet or physical activity. We will assess the incidence of diabetes and pre-diabetes, and the influence of TIPS on nutritional status and sarcopenia. Patients will be follow-up 6 months after TIPS. We will explore the hormonal mechanisms that explain these changes.

Eligibility Criteria:
Inclusion Criteria:

* patient cirrhosis and portal hypertension justifying a treatment with TIPS
* written consent.

Exclusion Criteria:

* contraindication for TIPS
* indications of TIPS in emergency or as part of the preparation for a surgical procedure,
* hepatocellular carcinoma outside Milan criteria or cancer at a palliative stage,
* a contra-indication to the realization of an OGTT,
* a hyperglycemic treatment (corticosteroids, somatostatin, etc.),
* hemoglobin \<7 g / dl,
* patients who have had a liver transplant,
* those for whom the follow-up is considered impossible or the vital prognosis is engaged in the short term,
* pregnant or lactating women,
* those unable to receive enlightened information,
* those participating in interventional research
* and finally the persons placed under safeguard of justice, tutelage or curatorship.
Profile of Pain and Unpleasant Sensations in Patients With Referred Pain

This feasibility study primarily aimed to assess the technology acceptance and usability of a pain tracking software in patients with spinally referred chronic pain. The secondary aim was to assess the fluctuations in pain intensity and distribution, using the pain tracking software during a 3-month period. Additionally, the study aimed to explore the patients' behavior when self-reporting pain when given the opportunity to use a variety of pain quality descriptors, such as tingling, burning and stabbing.

Patients with spinally referred chronic pain will be recruited to participate. Participants will be asked to use a pain tracking software to create weekly pain reports for a 3-month period. These pain reports consist of pain drawings and intensity scales. Additionally, patients will complete baseline disability and pain catastrophizing online questionnaires. The project does not affect treatment or does not offer any intervention.


Eligibility Criteria:
Inclusion Criteria:

* Suffer from pain in the neck or lumbar spine referring to a limb for a more than 7 consecutive days
* Participant is willing and able to give informed consent for participation in the study.

Exclusion Criteria:

* Pregnancy or breastfeeding, severe infections, cancer.
* Epilepsy, Multiple sclerosis, history of stroke, diabetes, traumatic spinal cord injury resulting in permanent functions loss
* Lack of ability to cooperate due to language barrier, cognition or inability to use technology.
Comparison of Different Energy Sources During TUR-P

With this study, it is aimed to compare the operative results and complication rates in transurethral resection of the prostate (TUR-P) performed by resectoscopes with two different bipolar and a monopolar energy sources.

Following data will be collected and evaluated prospectively for the three groups of patients who will undergo TUR-P due to benign prostate hyperplasia (BPH) with one of the resectoscopes using different energy sources:

1. Preoperative data: age, height, weight, body-mass index, concomitant morbidities, use of any drug, history of operation, duration of lower urinary tract symptoms, history of any previous treatment taken for BPH, serum level of prostate specific antigen, prostate volume, maximum and average urine flow rate, postmicturation residual urine volume, hemoglobin level
2. Operative data: duration of operation, volume of resected tissue, observation of obturator reflex (if any), kind and size of the urethral catheter used
3. Postoperative data: time to removal of urethral catheter, hospitalization duration, change in hemoglobin, rate of blood transfusion, any other complications

Eligibility Criteria:
Inclusion Criteria:

* Having an indication due to BPH
* Aged between 40 and 80 years old

Exclusion Criteria:

* Kidney failure due to BPH
* Any kind of coagulopathy or use of anticoagulants in the preoperative period
* History of any previous open or endoscopic prostate surgery
Familial Dysglobulinemia

Multiple Myeloma (MM) is a malignant proliferation of monoclonal plasma cells. Myeloma accounts for almost 14% of all hematologic cancers and is essentially incurable. Myeloma commonly evolves from a precursor disease, Monoclonal gammopathy of undetermined significance (MGUS). Despite intensive study, the etiology of MGUS and myeloma are unknown and no lifestyle or environmental exposure factors have been identified that are consistently linked to increased risk of MM, MGUS or the transition between the two.

The overall goal is to identify risk genes for dysglobulinemia, and more specifically Multiple Myeloma. This will involve the conservation of cells in a bank and genetic sequencing on samples obtained from families with at least two cases of dysglobulinemia. Material used for sequencing is likely to include fresh peripheral blood cells or lymphoblastoid lines established from peripheral blood lymphocytes of patients.


Eligibility Criteria:
Inclusion Criteria:

* 2 cases per family at least
* 1 case alive at least
* biological material available for 1 case at least
* Patients give their informed consent
* attached to the French Health protection service

Exclusion Criteria:

* Age under 18
A Facebook-based Weight Loss Programme for Obese Adults in Hong Kong

The purpose of this study is to determine the feasibility and efficacy of a 6-month weight loss intervention program for obese working adults through a popular social networking site - Facebook.

Obese individuals often are at higher risk for developing non-communicable diseases such as diabetes and cardiovascular disease. The regular physical activity, healthy diet and social support have been shown to be beneficial for weight loss.

This is a two-arm parallel design randomized controlled trial for 6 months. Participants who completed the baseline assessment will be randomly allocated, after stratified by gender, to either a control group or Facebook-based intervention group. The control group will receive information on healthy eating, physical activity, obesity and cancer via three government printed health pamphlets. In addition to the government health pamphlets, the intervention group will receive a programme delivered through Facebook.

The interventions include participation in a private research group on Facebook for health education, self monitoring and social support. Participants will receive 12 weekly lessons related to nutrition, physical activity, Chinese food therapy, acupressure, weight loss. A registered nutritionist and a registered Chinese medicine practitioner will join the Facebook group as health partners. Both of them are also registered nurses.

Data collection will be carried out at baseline, 3 months and 6 months. Each time, both groups will complete online questionnaires and attend in-person anthropometric measurements

Eligibility Criteria:
Inclusion Criteria:

* university full-time employees;
* age 18 to 60 years,
* BMI of 25 to 40 kg/m2,
* have access to Internet and Facebook;
* able to communicate in both English and Chinese at F.5 secondary school level or above.
* agree to communicate with Internet, email, Facebook group and respect privacy.

Exclusion Criteria:

* Smoker;
* an unstable medical or mental status;
* history of myocardial infarction or stroke, or cancer in the past 5 years;
* orthopedic or joint problems that would prohibit exercise;
* in treatment for alcohol or drug dependency;
* an eating disorder;
* pregnant, breastfeeding, or planning on becoming pregnant within the next 6 months;
* use of medication that might affect body weight;
* a recent weight loss of more than 4.5 kg in the previous 6 months;
* currently participating in a weight loss program;
* organic obesity;
* unable to attend assessments or increase physical activity.
Anesthetic Complication Among Acute Ischemic Stroke Patients During Endovascularization Therapy

Retrospective descriptive study

Retrospective chart review from January 2014 to December 2015

Eligibility Criteria:
Inclusion Criteria:

- Acute ischemic stroke patients who received endovascular therapy from January 2015 to December 2016

Exclusion Criteria:

- Age less than 18 years old
MAnagement of METastatic Disease in Campania (MAMETIC)

The MAMETIC Trial represents the first regional epidemiological study that aims to evaluate patients living in Campania with metastatic cancer, with the intent to detect different prevalence of tumors in the metastatic phase and evaluate the local response to the patient's request for assistance.

Condition or disease: Metastatic disease Intervention/treatment: Radiation Treatment

The MAMETIC Trial is a multicenter, retrospective and prospective observational study and 17 of 20 RT Centers in Campania joined it.

1. The retrospective part of the study concerns all patients enrolled with a diagnosis of metastatic disease and treated in RT centers of the Campania Region with 3DCRT, IMRT, VMAT, SBRT techniques from January 2019 to August 2020. In 2019, it has been enrolled 12.500 patients in the 17 RT Centers and it is estimated that 20-30% of the above mentioned patients had metastasis. Thus, approximately 2.560 patients are expected to be enrolled.
2. The prospective part of the study is going to enroll all metastatic patients eligible for palliative RT, treated in RT Centers of the Campania region with 3DCRT, IMRT, VMAT, SBRT techniques from September 2020 to September 2025. Considering the RT Centers that joined the trial, it is expected to enroll approximately 2.500-4.200 patients per year and a total of 12.500-21.000 patients in 5 years.

The study will last 61 months, divided as follow: 60 months of enrollment phase and up to 1 month of follow-up for pain and bone metastasis patients. Follow-up will be performed on the 15th and 30th day after the end of radiation treatment.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged \> 18 years resident in Campania Region;
* Patients diagnosed with metastatic disease candidates for radiotherapy
* Metastatic patients candidates for radiotherapy re-treatment
* Oligometastatic patients candidates for radiotherapy; Patients who have given their consent

Exclusion Criteria:

* Patients aged \< 18 years
* Patients who are unable to express consent to sensitive data and radiant treatment